Positive Biosciences Expands to Chennai- identifying medical institutions for strategic partnerships


Advertisements



April 27,  16.33 PM IST || Pocket News Alert

Positive Biosciences, the leading genomics testing company is setting up its presence in Chennai, to meet the emergent demand from the region. With the increasing number of diabetics, stroke and cancer patients, there is an increasing need for individuals to receive a complete health risk assessment. The company uses big data and artificial intelligence to predict disease risk in healthy individuals and best treatment options in cancer patients. This analysis helps clinicians personalize the clinical management of cancer and other health conditions. Chennai, considered as the Health Capital of India, is a destination for medical tourists attracting about 45% of all health tourists arriving in India from abroad in addition to 30% to 40% of domestic tourists. With genomics testing being part of the healthcare regime in many countries, Positive Bioscience’s presence in Chennai will provide this latest technology to hospitals and medical practitioners.  The company aims to launch its Personal Genomics and Cancer Genomics portfolio of services in Chennai.

Positive Biosciences Expands to Chennai- identifying medical institutions for strategic partnerships


Says Samarth Jain, CEO Positive Biosciences, “Chennai, is an important centre for treatment of Cancer for patients in India, as well as those patients who come from other countries. The cancer genomic tests will help oncologists diagnose and treat patients with more precision and lesser suffering.  It is only natural for us to strengthen our presence in this region to respond to the growing needs of medical practitioners.  We are gearing to meet the emergent demands from this region by strengthening our hospital network, discussing partnership opportunities to advance Personal Genomics testing as well as Cancer genomics for cancer prevention, diagnosis, and treatment. “
Positive Bioscience has tie ups with major hospitals in Mumbai and Delhi including Medanta, Kokilaben Dhirubhai Ambani Hospital, Saifee Hospital and Breach Candy. Says Samarth Jain “ The response from the doctors across these hospitals has been amazing. These hospitals are modern and provide the best medical care. For us our contribution towards saving lives and helping people be healthy, is what drives us.”

As per data by the Indian Council of Medical Research, about 88,847 new cancer cases are expected to be in Tamil Nadu by 2016, or 8% of the total number of cases in the country.  Though clinical genomics is already popular in the western countries where about 1 in every 10 cancer patients are undergoing genetic testing to guide their treatment, in India this number is extremely poor. Only 1 in 10, 000 patients undergo genomic testing. Positive Bioscience aspires to expand the effective use of genomics in the cancer treatment. Dedicating itself to make a difference in patients’ lives, Positive Bioscience will offer a variety of services in the domain of personal genomics, cancer genomics, and molecular diagnostics.

Says Dr.T. Raja MD.DM.Senior Medical Oncologist, Apollo Speciality Hospital, Chennai "Personalized medicine is the future of cancer treatment.  It is becoming a reality today with the availability of such cutting-edge genomic tests.  We are more advanced in treating or curing cancer when compared to a decade or so back. Still prevention and early diagnosis is critical. The combination of prevention through Personal Genomics testing, and personalised treatment through Cancer genomic testing is a multi pronged attack for saving lives.  Using genetic profiling, we can give specific drugs for different types of cancers, increasing survival rates". Dr. Raja Sundaram, Senior Surgical Oncologist, SIMS Chennai. adds "Genomics is transforming cancer care worldwide. Genomics tests helps in personalizing treatment for each patient as per his or her genetic makeup. Such test are already very popular in the developed countries and we are glad that now it's available in Chennai as well. This will be very instrumental in our fight against cancer." says Dr S Krishnan, Director, Srinivasan Rajalakshmi Memorial Hospital, Chennai" In the era of Personalized evidence based cancer treatment, Positive Bioscience will help doctors and patients to have a tailor made treatment avoiding ineffective and toxic treatments."

Positive Bioscience has developed a comprehensive strategy & roadmap for the integration of such cutting-edge genomic testing into the clinical practice at Hospitals. The company is identifying medical institutions for strategic partnerships.

Positive Biosciences uses its deep genomics expertise to offer comprehensive clinical genomics tests and genetic counselling services in disease specialty areas such as cancer, rare disease, cardiology, ophthalmology, and diabetes.

About Positive Bioscience: Positive Bioscience is India's leading clinical genomics company using big data and artificial intelligence to predict disease risk in healthy individuals and best treatment options in cancer patients. Positive Bioscience believes in providing world-class molecular genetic testing and markets tests in Cancer Genomics that are targeted for guiding treatment in cancer patients and Personal Genomics tests that are targeted to healthy individuals for predicting disease risk and preventing it.

Started in October 2012 by Samarth Jain Positive Bioscience always brought the latest genomics technology in India. It launched India’s first comprehensive cancer genomics test in 2014. It also opened India’s first Personal Genomics clinic in Medanta, The Medicity in August 2014. Company also is the first to commercialize Whole Genome Sequencing for personal Genomics and circulating tumour DNA test in cancer genomics. Positive Bioscience is also an exclusive partner of Myriad Genetics USA, world’s leading molecular diagnostics company well known for inventing BRCA gene testing.

Positive Bioscience recently introduced for the first time in India the whole RNA sequencing test commercially for cancer.

All the tests are carried out in NABL/CAP/CLIA accredited laboratories in India, USA, China or Korea.